Link to XBRL Interactive Data 30 June 2018

September 3, 2018 Kerry Rowe

https://www.sec.gov/cgi-bin/viewer?action=view&cik=1131343&accession_number=0001144204-18-047425&xbrl_type=v

PBT434 data to be presented at the International Congress of Parkinson’s Disease and Movement Disorders

Pre-clinical evidence demonstrates PBT434 as a potential treatment for MSA

Dr David Stamler China Investor & Partnering Symposium Webcast

March 15, 2018

Alterity Therapeutics Announces Successful Completion of Phase 1 Clinical Trial

July 29, 2019July 29, 2019

Prana presents new benchmark test to assess Huntington’s Disease patients in clinical trials

July 17, 2013

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Link to XBRL Interactive Data 30 June 2018

Related Posts

Dr David Stamler China Investor & Partnering Symposium Webcast

Alterity Therapeutics Announces Successful Completion of Phase 1 Clinical Trial

Prana presents new benchmark test to assess Huntington’s Disease patients in clinical trials